210 related articles for article (PubMed ID: 10623705)
1. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
Harris JE; Ryan L; Hoover HC; Stuart RK; Oken MM; Benson AB; Mansour E; Haller DG; Manola J; Hanna MG
J Clin Oncol; 2000 Jan; 18(1):148-57. PubMed ID: 10623705
[TBL] [Abstract][Full Text] [Related]
2. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Vermorken JB; Claessen AM; van Tinteren H; Gall HE; Ezinga R; Meijer S; Scheper RJ; Meijer CJ; Bloemena E; Ransom JH; Hanna MG; Pinedo HM
Lancet; 1999 Jan; 353(9150):345-50. PubMed ID: 9950438
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
5. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.
Hoover HC; Brandhorst JS; Peters LC; Surdyke MG; Takeshita Y; Madariaga J; Muenz LR; Hanna MG
J Clin Oncol; 1993 Mar; 11(3):390-9. PubMed ID: 8445413
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
[TBL] [Abstract][Full Text] [Related]
9. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
10. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Grant SC; Kris MG; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jun; 5(6):1319-23. PubMed ID: 10389914
[TBL] [Abstract][Full Text] [Related]
11. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
[TBL] [Abstract][Full Text] [Related]
12. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine.
Hoover HC; Surdyke M; Dangel RB; Peters LC; Hanna MG
Cancer Res; 1984 Apr; 44(4):1671-6. PubMed ID: 6704973
[TBL] [Abstract][Full Text] [Related]
13. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Baars A; Claessen AM; van den Eertwegh AJ; Gall HE; Stam AG; Meijer S; Giaccone G; Meijer CJ; Scheper RJ; Wagstaff J; Vermorken JB; Pinedo HM
Ann Oncol; 2000 Aug; 11(8):965-70. PubMed ID: 11038032
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.
Hanna MG; Hoover HC; Vermorken JB; Harris JE; Pinedo HM
Vaccine; 2001 Mar; 19(17-19):2576-82. PubMed ID: 11257395
[TBL] [Abstract][Full Text] [Related]
15. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
16. Combined surgical and immunotherapeutic treatment of patients with fourth stage colon cancer.
Tarasov VA; Filatov MV; Kisliakova TV; Noskov FS; Koloskov AV; Stavrovietski VV; Onikienko SB; Kletchikov VZ; Lvov IV; Yu Varfolomeeva E; Blizniukov OP; Levina VV; Kiselevski MV
Hybridoma; 1999 Feb; 18(1):99-102. PubMed ID: 10211796
[TBL] [Abstract][Full Text] [Related]
17. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
19. Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
Berger M; Kreutz FT; Horst JL; Baldi AC; Koff WJ
J Pharm Pharm Sci; 2007; 10(2):144-52. PubMed ID: 17706173
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
